Results 211 to 220 of about 3,960,591 (302)

Early Ibrutinib Dose Modifications in CLL: A Post Hoc Analysis of the Real-World EVIdeNCE Study. [PDF]

Cancers (Basel)
Molica S, Scalzulli PR, Scarfò L, Minoia C, Murru R, Sportoletti P, Albano F, Di Renzo N, Sanna A, Laurenti L, Massaia M, Cassin R, Coscia M, Patti C, Pennese E, Tafuri A, Chiarenza A, Galieni P, Perbellini O, Selleri C, Califano C, Ferrara F, Cuneo A, Murineddu M, Palumbo G, Scortechini I, Tedeschi A, Trentin L, Varettoni M, Pane F, Merli F, Morello L, Musuraca G, Tani M, Ibatici A, Palma M, Arienti D, Mauro FR.   +37 more
europepmc   +1 more source

Digital twins to accelerate target identification and drug development for immune‐mediated disorders

FEBS Open Bio, EarlyView.
Digital twins integrate patient‐derived molecular and clinical data into personalised computational models that simulate disease mechanisms. They enable rapid identification and validation of therapeutic targets, prediction of drug responses, and prioritisation of candidate interventions.
Anna Niarakis, Philippe Moingeon
wiley   +1 more source

Initial Real-World Evidence for Lecanemab in the United States. [PDF]

Drugs Aging
Brixner DI, Zhao C, Toyosaki H, Frech FH, Rosenbloom MH.   +4 more
europepmc   +1 more source

Large‐scale bidirectional arrayed genetic screens identify OXR1 and EMC4 as modifiers of αSynuclein aggregation

FEBS Open Bio, EarlyView.
Activation of the mitochondrial protein OXR1 increases pSyn129 αSynuclein aggregation by lowering ATP levels and altering mitochondrial membrane potential, particularly in response to MSA‐derived fibrils. In contrast, ablation of the ER protein EMC4 enhances autophagic flux and lysosomal clearance, broadly reducing α‐synuclein aggregates.
Sandesh Neupane, Lea Nikolić, Lorenzo Maraio, Thomas Goiran, Nathan Karpilovsky, Stefano Sellitto, Vangelis Bouris, Jiang‐An Yin, Ronald Melki, Edward A Fon, Adriano Aguzzi, Elena De Cecco   +11 more
wiley   +1 more source

AI Triage in Primary Care: Building Safer and More Equitable Real-World Evidence.

J Med Internet Res
Alamoudi A, Kontopantelis E, Zghebi SS, Brown B.   +3 more
europepmc   +1 more source

Social inequities and clinical outcomes in young women with cervical cancer: Real-world evidence. [PDF]

PLoS One
Cupertino Bérgomi L, de Souza Carvalho G, Zanetti de Albuquerque L, Gonçalves Kischinhevsky D, Dos Santos ALS, de Freitas Maciel L, Ávila Small I, Lopes da Silva J, de Melo AC.   +8 more
europepmc   +1 more source

Why human connection is the true metric of research success

FEBS Open Bio, EarlyView.
Human‐centred mentorship can be shaped by mentor attributes, actions, intrinsic drive and career ambition. Drawing on reflections across Singapore and France, as well as workshop insights from FEBS‐IUBMB ENABLE 2024, this article shows that human‐centred mentorship creates the conditions for sustainable growth, well‐being and retention in research ...
Timothy Lin Yun Tan, Mattias Wei Ren Kon, Xavier Coumoul, Fun Man Fung   +3 more
wiley   +1 more source

Beyond Methodological Considerations: Clinical Implications of Real-World Evidence from the CARE Study [Response to Letter]. [PDF]

J Pain Res
Überall MA, Müller-Schwefe PCG, Küster MA, Müller-Schwefe GHH.   +3 more
europepmc   +1 more source

Blood‐based proteomic profiling reveals context‐dependent changes in BCL2‐associated signaling during taxane therapy in breast cancer patients

FEBS Open Bio, EarlyView.
Chemotherapy side effects significantly impact cancer survivors' quality of life. Using protein levels in blood samples from breast cancer patients before and after 12 weeks of taxane treatment, we detected treatment‐dependent changes in calcium signaling and aging pathways associated with cancer recurrence.
Saira Munshani, Eiman Y. Ibrahim, Rozalyn L. Rodwin, Leah M. Ferrucci, Kim Blenman, Maryam Lustberg, Barbara E. Ehrlich   +6 more
wiley   +1 more source